ABOS Earnings
Acumen Pharmaceuticals Inc
$
1.570
Earning Analysis
Welcome to our in-depth analysis of Acumen Pharmaceuticals Inc(ABOS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Acumen Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: %
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-11-12 | Pre-Market | -0.63 | -0.44 | +30.16 | - | 0.00 | - | -1.02 | -19.80 |
| FY2025Q2 | 2025-08-12 | Pre-Market | -0.54 | -0.68 | -25.93 | - | 0.00 | - | -11.27 | - |
| FY2025Q1 | 2025-05-13 | Pre-Market | -0.56 | -0.48 | +14.29 | - | 0.00 | - | - | +1.90 |
| FY2024Q4 | 2025-03-27 | Pre-Market | -0.47 | -0.62 | -31.91 | - | 0.00 | - | +6.03 | -5.17 |
| FY2024Q2 | 2024-08-13 | Pre-Market | -0.28 | -0.34 | -21.43 | - | 0.00 | - | +8.20 | +10.55 |
| FY2024Q1 | 2024-05-14 | - | -0.23 | -0.25 | -8.70 | - | - | - | +9.82 | +14.29 |
| FY2023Q4 | 2024-03-26 | - | -0.29 | -0.29 | - | - | - | - | -11.76 | -10.82 |
| FY2023Q3 | 2023-11-13 | - | -0.31 | -0.24 | +22.58 | - | - | - | +6.84 | +20.00 |
| FY2023Q2 | 2023-08-08 | - | -0.36 | -0.28 | +22.22 | - | - | - | - | +3.14 |
| - | 2023-05-09 | - | -0.33 | -0.28 | +15.15 | - | - | - | +18.14 | +27.84 |
ABOS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Acumen Pharmaceuticals Inc reported performance for FY2025Q3, announced on 2025-11-12. The company achieved an EPS of -0.44, compared to analyst estimates of -0.63 by 30.16% . Revenue for the quarter reached 0.00 compared to expectations of 0.00 by % .
The stock price reacted with a -1.02% one-day change and a -19.80% five-day change following the earnings release. These movements reflect market reaction in Acumen Pharmaceuticals Inc growth trajectory and strategic initiatives.
ABOS Earnings Forecast
Looking ahead, Acumen Pharmaceuticals Inc(ABOS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.36.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for have been Go Up by 2.61%, while EPS estimates have been No Change by %. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Acumen Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between ABOS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Stock Price
Go Up
+2.61%
In Past 3 Month
1Y
3Y
5Y
Fiscal Period
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price1.57
ABOS Revenue and EPS Performance: A Historical Perspective
Acumen Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-12,Pre-Market):
EPS: -0.44 (Actual) vs.-0.63 (Estimate) (30.16%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -1.02%(1-Day), -19.80%(5-Day)
FY2025Q2 (2025-08-12,Pre-Market):
EPS: -0.68 (Actual) vs.-0.54 (Estimate) (-25.93%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -11.27%(1-Day), 0.00%(5-Day)
FY2025Q1 (2025-05-13,Pre-Market):
EPS: -0.48 (Actual) vs.-0.56 (Estimate) (14.29%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 0.00%(1-Day), 1.90%(5-Day)
Earnings Reaction
The chart below shows how ABOS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABOS sees a +1.63% change in stock price 10 days leading up to the earnings, and a -4.62% change 10 days following the report. On the earnings day itself, the stock moves by +2.50%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -7.18% on the day following the earnings release and then changed by -19.49% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Summary
Neutral
2025-11-12
The company's financial health shows a net loss and a reliance on existing cash reserves, which is concerning. However, there is optimism in their strategic collaboration with JCR and ongoing trials, which could potentially lead to positive outcomes. The Q&A reveals cautious optimism and strategic planning, but also highlights uncertainties in clinical trial outcomes and financial sustainability. The lack of guidance and potential financial risks balance out the positive aspects, resulting in a neutral sentiment.
Acumen Pharmaceuticals Inc (ABOS) Q2 2025 Earnings Call Summary
Neutral
2025-08-12
The earnings call summary shows mixed signals: strong R&D progress and effective cost-reduction measures, but increased operational losses and supply chain risks. The Q&A highlighted positive feedback on the pTau217 test but lacked detailed guidance on key metrics. No new partnerships or secondary offerings were announced. Financial health remains stable, but the absence of immediate catalysts and ongoing risks suggest a neutral stock price movement in the short term.
Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Summary
Neutral
2025-05-14
The earnings call revealed mixed signals: strong enrollment and innovative methods in clinical trials, but significant financial losses and no clear shareholder return plan. The Q&A didn't reveal any major risks but highlighted competitive pressures and financial challenges. The EPS beat expectations, but with no year-over-year improvements in losses. The lack of new partnerships or guidance changes suggests a neutral market reaction.
Acumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Summary
Neutral
2025-05-13
The earnings call reflects a neutral sentiment due to mixed signals. The successful enrollment and subcutaneous administration study are positives, but the net loss and lack of interim analysis in the study are concerns. The Q&A highlights potential competitive pressures and regulatory risks, but no immediate threats to the trial are evident. Without clear guidance or partnerships, the market may remain cautious, leading to a neutral stock price movement.
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Summary
Negative
2025-03-27
The earnings call reflects concerns about financial sustainability, with no shareholder return plan and significant losses reported. Despite positive developments in product formulation and research engagement, competitive pressures and regulatory risks persist. The Q&A session highlighted management's vague responses and lack of clarity on biomarker relevance, adding uncertainty. Without strong financial guidance or a shareholder return plan, the stock price reaction is likely negative.
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Summary
Neutral
2025-03-27
The earnings call highlights successful clinical progress and strong cash reserves, but also reveals financial risks and lack of shareholder return plans. The Q&A section shows management's cautious optimism but vague responses on certain biomarkers. Given these mixed signals, the stock price is likely to remain stable in the short term, with a neutral sentiment prevailing.
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Summary
Neutral
2024-11-12
The earnings call reveals mixed signals. While the company maintains a solid cash position and efficient trial enrollment, it faces significant financial losses and competitive pressures. The Q&A section highlights uncertainties around future trial data and market adoption. Despite the positive enrollment progress and cash runway, lack of clear guidance on subcutaneous development and existing market competition temper optimism. With no major catalysts or guidance changes, the stock price is likely to remain stable over the next two weeks.
People Also Watch
HNNA
Hennessy Advisors Inc
10.070
USD
-0.59%
CRDL
Cardiol Therapeutics Inc
0.973
USD
+0.83%
LPTX
Leap Therapeutics Inc
0
USD
+78.63%
RECT
Rectitude Holdings Ltd
2.000
USD
-4.31%
LNSR
LENSAR Inc
9.830
USD
+1.34%
SUNS
Sunrise Realty Trust Inc
9.700
USD
+3.63%
MGX
Metagenomi Inc
1.510
USD
0.00%
MDXH
MDxHealth SA
3.320
USD
+2.15%
FRD
Friedman Industries Inc
19.680
USD
+1.81%
SDST
Stardust Power Inc
3.250
USD
-6.88%
FAQ
What were the key highlights of ABOS’s latest earnings report for FY2025Q3?
ABOS reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.44, surpassing the expected -0.63 by 30.16% . The stock experienced a -1.02% price change on the earnings day and a -19.8% change over the next five days, reflecting market reactions to the results.
How did ABOS’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for ABOS for undefined?
How does ABOS’s stock price correlate with earnings forecast revisions?
What should investors expect from ABOS’s next earnings report?